Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL
Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment
UGN-102 Induces Clinically Meaningful CR Rates in Low-Grade, Intermediate-Risk NMIBC
Orca-T Is a Safe Addition to HSCT-RIC in Advanced Hematologic Malignancies
